Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines about artificial intelligence. Everyone's talking about AI right now. But see, I've been talking about it for years.

I call it my AI Retirement Playbook. I recommend you check it out now.

Kathryn B. McKenzie net worth and biography

Kathryn McKenzie Biography and Net Worth

CFO of NeoGenomics

Kathryn McKenzie serves as Chief Sustainability and Risk Officer for NeoGenomics. In this role, she oversees our environmental, social and governance initiatives as well as our risk management activities.

She joined NeoGenomics in 2017 as our Chief Accounting Officer and Vice President of Finance and was most recently our Chief Financial Officer through December 2021. Prior to joining NeoGenomics, Ms. McKenzie served in various roles at Chico’s FAS, including as Assistant Controller and had responsibilities for SEC reporting, accounting, cash management and treasury. Ms. McKenzie began her career at Ernst and Young in assurance, primarily serving financial institutions and healthcare clients. Ms. McKenzie is a Certified Public Accountant and holds a Master's of Science in Accountancy from the University of North Carolina Wilmington.

What is Kathryn B. McKenzie's net worth?: The estimated net worth of Kathryn B. McKenzie is at least $176,181.95 as of December 10th, 2019. Ms. McKenzie owns 10,273 shares of NeoGenomics stock worth more than $176,182 as of December 25th. This net worth evaluation does not reflect any other investments that Ms. McKenzie may own. Learn More about Kathryn B. McKenzie's net worth.
How do I contact Kathryn B. McKenzie?: The corporate mailing address for Ms. McKenzie and other NeoGenomics executives is 12701 COMMONWEALTH DRIVE SUITE 9, FORT MYERS FL, 33913. NeoGenomics can also be reached via phone at (239) 768-0600 and via email at [email protected]. Learn More on Kathryn B. McKenzie's contact information.
Has Kathryn B. McKenzie been buying or selling shares of NeoGenomics?: Kathryn B. McKenzie has not been actively trading shares of NeoGenomics over the course of the past ninety days. Most recently, Kathryn B. Mckenzie sold 1,846 shares of the business's stock in a transaction on Tuesday, December 21st. The shares were sold at an average price of $35.00, for a transaction totalling $64,610.00. Learn More on Kathryn B. McKenzie's trading history.
Who are NeoGenomics' active insiders?: NeoGenomics' insider roster includes (), Douglas Brown (Insider), George Cardoza (Insider), Bruce Crowther (Director), Mark Mallon (CEO), Kathryn McKenzie (CFO), and Robert Shovlin (Insider). Learn More on NeoGenomics' active insiders.
Are insiders buying or selling shares of NeoGenomics?: During the last year, insiders at the medical research company sold shares 2 times. They sold a total of 7,762 shares worth more than $118,189.52. The most recent insider tranaction occured on November, 15th when General Counsel Alicia C Olivo sold 5,175 shares worth more than $79,488.00. Insiders at NeoGenomics own 1.3% of the company. Learn More about insider trades at NeoGenomics.
Information on this page was last updated on 11/15/2024.

Kathryn B. McKenzie Insider Trading History at NeoGenomics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
12/21/2021	Sell	1,846	$35.00	$64,610.00
12/10/2019	Sell	8,000	$26.37	$210,960.00	10,273

Kathryn B. McKenzie Buying and Selling Activity at NeoGenomics

NeoGenomics Company Overview

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization. NeoGenomics, Inc. was founded in 2001 and is headquartered in Fort Myers, Florida.

Today's Range

Now: $17.15

$16.29

$17.17

50 Day Range

MA: $15.86

$13.05

$18.43

2 Week Range

Now: $17.15

$12.77

$20.94

Volume

469,000 shs

Average Volume

805,794 shs

Market Capitalization

$2.20 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.24

Most People Are Dead Wrong.

From Brownstone Research | Ad